Ekso Bionics (EKSO) 10-Q 29 Jul 24 2024 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2024	Jul. 26, 2024
Document Information [Line Items]
Entity Central Index Key	0001549084
Entity Registrant Name	EKSO BIONICS HOLDINGS, INC.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2024
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2024
Document Transition Report	false
Entity File Number	001-37854
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	99-0367049
Entity Address, Address Line One	101 Glacier Point, Suite A
Entity Address, City or Town	San Rafael
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94901
City Area Code	510
Local Phone Number	984-1761
Title of 12(b) Security	Common Stock, $0.001 par value per share
Trading Symbol	EKSO
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		18,444,181

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Current assets:
Cash and restricted cash	$ 5,885	$ 8,638
Accounts receivable, net of allowances of $28 and $79, respectively	6,520	5,645
Inventories	4,974	5,050
Prepaid expenses and other current assets	1,263	875
Total current assets	18,642	20,208
Property and equipment, net	1,748	2,018
Right-of-use assets	989	977
Intangible assets, net	4,739	4,892
Goodwill	431	431
Other assets	435	392
Total assets	26,984	28,918
Current liabilities:
Accounts payable	2,125	1,847
Accrued liabilities	1,973	2,664
Deferred revenues, current	1,926	1,993
Note payable, current	1,250	1,250
Lease liabilities, current	430	363
Total current liabilities	7,704	8,117
Deferred revenues	2,016	2,169
Notes payable, net	4,352	4,832
Lease liabilities	659	723
Warrant liabilities	49	366
Other non-current liabilities	145	105
Total liabilities	14,925	16,312
Commitments and contingencies (Note 14)
Stockholders’ equity:
Convertible preferred stock, $0.001 par value; 10,000 shares authorized; none issued and outstanding at June 30, 2024 and December 31, 2023	0	0
Common stock, $0.001 par value; 141,429 shares authorized; 18,444 and 14,848 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively	19	15
Additional paid-in capital	256,491	251,580
Accumulated other comprehensive income	539	156
Accumulated deficit	(244,990)	(239,145)
Total stockholders’ equity	12,059	12,606
Total liabilities and stockholders’ equity	$ 26,984	$ 28,918

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) shares in Thousands, $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Allowance for doubtful accounts	$ 28	$ 79
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	10,000	10,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized (in shares)	141,429	141,429
Common stock, issued (in shares)	18,444	14,848
Common stock, outstanding (in shares)	18,444	14,848

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Revenue	$ 4,950	$ 4,703	$ 8,706	$ 8,825
Cost of revenue	2,313	2,449	4,118	4,571
Gross profit	2,637	2,254	4,588	4,254
Operating expenses:
Sales and marketing	1,846	2,349	3,664	4,437
Research and development	1,116	1,398	2,252	2,552
General and administrative	2,010	2,791	4,263	5,997
Total operating expenses	4,972	6,538	10,179	12,986
Loss from operations	(2,335)	(4,284)	(5,591)	(8,732)
Other (expense) income, net:
Interest expense, net	(74)	(61)	(131)	(172)
Loss on modification of warrant	0	0	(109)	0
Gain on revaluation of warrant liabilities	84	152	426	126
Unrealized (loss) gain on foreign exchange	(91)	(7)	(440)	210
Other expense, net	0	(30)	0	(51)
Total other (expense) income, net	(81)	54	(254)	113
Net loss	(2,416)	(4,230)	(5,845)	(8,619)
Other comprehensive income (loss)	92	(10)	383	(204)
Comprehensive loss	$ (2,324)	$ (4,240)	$ (5,462)	$ (8,823)
Net loss per share applicable to common shareholders, basic and diluted (in dollars per share)	$ (0.13)	$ (0.31)	$ (0.33)	$ (0.64)
Weighted average number of common shares outstanding, basic and diluted (in shares)	18,224	13,637	17,822	13,467

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2022	0	13,203
Balance at Dec. 31, 2022	$ 0	$ 13	$ 248,813	$ 563	$ (223,947)	$ 25,442
Net loss	$ 0	$ 0	0	0	(4,389)	(4,389)
Equity incentive plan (in shares)	0	139
Stock-based compensation expense	$ 0	$ 0	424	0	0	424
Foreign currency translation adjustments	$ 0	$ 0	0	(194)	0	(194)
Balance (in shares) at Mar. 31, 2023	0	13,342
Balance at Mar. 31, 2023	$ 0	$ 13	249,237	369	(228,336)	21,283
Balance (in shares) at Dec. 31, 2022	0	13,203
Balance at Dec. 31, 2022	$ 0	$ 13	$ 248,813	563	(223,947)	25,442
Net loss						(8,619)
Matching contribution to 401(k) plan (in shares)			161
Matching contribution to 401(k) plan			$ 249
Balance (in shares) at Jun. 30, 2023	0	13,807
Balance at Jun. 30, 2023	$ 0	$ 14	250,000	359	(232,566)	17,807
Balance (in shares) at Mar. 31, 2023	0	13,342
Balance at Mar. 31, 2023	$ 0	$ 13	249,237	369	(228,336)	21,283
Net loss	$ 0	$ 0	0	0	(4,230)	(4,230)
Matching contribution to 401(k) plan (in shares)	0	161
Matching contribution to 401(k) plan	$ 0	$ 0	249	0	0	249
Equity incentive plan (in shares)	0	304
Stock-based compensation expense	$ 0	$ 0	514	0	0	514
Foreign currency translation adjustments	$ 0	0	0	(10)	0	(10)
Equity incentive plan		$ 1				1
Balance (in shares) at Jun. 30, 2023	0	13,807
Balance at Jun. 30, 2023	$ 0	$ 14	250,000	359	(232,566)	17,807
Balance (in shares) at Dec. 31, 2023	0	14,848
Balance at Dec. 31, 2023	$ 0	$ 15	251,580	156	(239,145)	12,606
Net loss	$ 0	$ 0	0	0	(3,429)	(3,429)
Equity financing, net (in shares)	0	2,997
Equity financing, net	$ 0	$ 3	3,967	0	0	3,970
Matching contribution to 401(k) plan (in shares)	0	163
Matching contribution to 401(k) plan	$ 0	$ 0	237	0	0	237
Equity incentive plan (in shares)	0	88
Stock-based compensation expense	$ 0	$ 0	376	0	0	376
Foreign currency translation adjustments	$ 0	$ 0	0	291	0	291
Balance (in shares) at Mar. 31, 2024	0	18,096
Balance at Mar. 31, 2024	$ 0	$ 18	256,160	447	(242,574)	14,051
Balance (in shares) at Dec. 31, 2023	0	14,848
Balance at Dec. 31, 2023	$ 0	$ 15	$ 251,580	156	(239,145)	12,606
Net loss						(5,845)
Matching contribution to 401(k) plan (in shares)			163
Matching contribution to 401(k) plan			$ 238
Balance (in shares) at Jun. 30, 2024	0	18,444
Balance at Jun. 30, 2024	$ 0	$ 19	256,491	539	(244,990)	12,059
Balance (in shares) at Mar. 31, 2024	0	18,096
Balance at Mar. 31, 2024	$ 0	$ 18	256,160	447	(242,574)	14,051
Net loss	$ 0	$ 0	0	0	(2,416)	(2,416)
Equity financing, net (in shares)	0	75
Equity financing, net	$ 0	$ 0	47	0	0	47
Equity incentive plan (in shares)	0	273
Stock-based compensation expense	$ 0	$ 0	284	0	0	284
Foreign currency translation adjustments	$ 0	0	0	92	0	92
Equity incentive plan		$ 1
Balance (in shares) at Jun. 30, 2024	0	18,444
Balance at Jun. 30, 2024	$ 0	$ 19	$ 256,491	$ 539	$ (244,990)	$ 12,059

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Operating activities:
Net loss	$ (5,845)	$ (8,619)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	803	842
Changes in provision for credit losses on accounts receivable	39	16
Gain on revaluation of warrant liabilities	(426)	(126)
Stock-based compensation expense	660	938
Loss on modification of warrant	109	0
Common stock contribution to 401(k) plan	113	219
Unrealized loss (gain) on foreign currency transactions	440	(210)
Changes in operating assets and liabilities:
Accounts receivable	(1,029)	(518)
Inventories	(9)	(283)
Prepaid expenses and other assets, current and noncurrent	(387)	(62)
Accounts payable	281	(13)
Accrued, lease and other liabilities, current and noncurrent	(681)	(61)
Deferred revenues	(204)	760
Net cash used in operating activities	(6,136)	(7,117)
Investing activities:
Acquisition of property and equipment	(8)	(97)
Net cash used in investing activities	(8)	(97)
Financing activities:
Principal payments under note payable	(625)	0
Proceeds from issuance of common stock, net	4,017	0
Net cash provided by financing activities	3,392	0
Effect of exchange rate changes on cash	(1)	(4)
Net decrease in cash	(2,753)	(7,218)
Cash and restricted cash at beginning of period	8,638	20,525
Cash and restricted cash at end of period	5,885	13,307
Supplemental disclosure of cash flow activities
Cash paid for interest	96	98
Cash paid for income taxes	8	32
Supplemental disclosure of non-cash activities
Transfer of inventory to (from) property and equipment	72	(131)
Initial recognition of operating lease liability and right of use asset	180	0
Share issuance RSU	1	0
Share issuance for common stock contribution to 401(k) plan	$ 238	$ 249

Note 1 - Organization

Note 1 - Organization	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	1. Organization Description of Business Ekso Bionics Holdings, Inc. (the “Company”) designs, develops, and markets wearable powered and non-powered exoskeleton products to augment human strength, endurance and mobility. The Company’s exoskeleton technology is primarily focused on aiding in the recovery and improved quality of life of individuals who have suffered from a variety of neurological conditions and allows for neurorehabilitation ranging from hospital to home, and also has technology that can be utilized by able-bodied users in the workplace. The Company has marketed devices that (i) enable individuals with neurological conditions affecting gait, including acquired brain injury ("ABI") and multiple sclerosis ("MS"), and spinal cord injury ("SCI") to rehabilitate and to stand and walk in neurorehabilitation settings and, for patients with a SCI, for home and community use, (ii) assist individuals with a broad range of upper extremity impairments, and (iii) allow industrial workers to perform difficult repetitive work for extended periods. Founded in 2005 , Liquidity and Going Concern As of June 30, 2024 six June 30, 2024 June 30, 2024 As described in Note 9. Notes Payable, net June 30, 2024 June 30, 2024 Our expectation to generate operating losses and negative operating cash flows in the future and the need for additional funding to support our planned operations raise substantial doubt regarding our ability to continue as a going concern for a period of one one no 12 The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The condensed consolidated financial statements do not

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation and Summary of Significant Accounting Policies and Estimates	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Basis of Presentation and Summary of Significant Accounting Policies and Estimates Basis of Presentation and Consolidation The accompanying condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10 December 31, 2023 March 4, 2024. In the opinion of management, the accompanying unaudited condensed consolidated financial statements have been prepared on a consistent basis with the audited consolidated financial statements for the fiscal year ended December 31, 2023 The results of operations for the three six June 30, 2024 not December 31, 2024 The condensed consolidated financial statements include the financial statements of Ekso Bionics Holdings, Inc. and its subsidiaries. All significant transactions and balances between Ekso Bionics Holdings, Inc. and its subsidiaries have been eliminated in consolidation. Use of Estimates The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. For the Company, these estimates include, but are not Foreign Currency The assets and liabilities of foreign subsidiaries and equity investments, where the local currency is the functional currency, are translated from their respective functional currencies into U.S. dollars at the rates in effect at the balance sheet date, and revenue and expense amounts are translated at average rates during the period, with resulting foreign currency translation adjustments recorded in accumulated other comprehensive income as a component of stockholders’ equity. Gains and losses from the re-measurement of balances denominated in currencies other than the entities' functional currencies, are recorded in other expense, net in the accompanying condensed consolidated statements of operations and comprehensive loss. Inventory Inventories are recorded at the lower of cost or net realizable value. Cost is computed using the standard cost method, which approximates actual cost on a first first Leases The Company records its leases in accordance with the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 842, Leases not may Lease expense is recognized over the expected lease term on a straight-line basis. Operating leases are recognized on the balance sheet as right-of-use assets, lease liabilities current and lease liabilities non-current. Leases with an initial term of 12 not Revenue Recognition The Company records its revenue in accordance with ASC 606, Revenue from Contracts with Customers five For multiple-element arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are determined based on observable prices at which the Company separately sells its products or services. If a standalone selling price is not The Company exercised judgement to determine that a product return reserve was not not Concentration of Credit Risk and Other Risks and Uncertainties Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and accounts receivable. The Company has significant cash balances at foreign financial institutions which throughout the year regularly exceed the applicable country cash deposit insurance limits of approximately $100 two $250 not Accounts receivable are derived from the sale of products shipped and services performed for customers primarily located in the U.S., Europe, Asia, and Australia. Invoices are aged based on contractual terms with the customer. The Company reviews accounts receivable for collectability and provides an allowance for potential credit losses. The allowance for potential credit losses on trade receivables reflects the Company’s best estimate of probable losses inherent in the accounts receivable balance based on known troubled accounts, historical experience, and other currently available evidence. Payment terms and conditions vary by contract type, although terms generally include a requirement of payment within 30 90 not June 30, 2024 December 31, 2023 Many of the sales contracts with customers outside of the U.S. are settled in a foreign currency other than the U.S. dollar. The Company does not not The Company had two 10% June 30, 2024 (15% and 10%), as no December 31, 2023 During the three June 30, 2024 two 10% ue (11% and 10%), as three three June 30, 2023 During the six June 30, 2024 two 10% nue (12% and 10%), a two six June 30, 2023 Recent Accounting Pronouncements In November 2023, No. 2023 07, 280 2023 07" 2023 07 2023 07 December 15, 2023, December 15, 2024. not 2023 07 Accounting Pronouncements Adopted in 2024 In August 2020, No. 2020 06, 2020 06" 2020 06 may first 2024 not

Note 3 - Accumulated Other Comp

Note 3 - Accumulated Other Comprehensive Income (Loss)	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Comprehensive Income (Loss) Note [Text Block]	3. Accumulated Other Comprehensive Income (Loss) The Company's accumulated other comprehensive income (loss) consists of the accumulated net unrealized gains or losses on foreign currency translation adjustments. The change in accumulated other comprehensive income (loss) presented on the condensed consolidated balance sheets for the six June 30, 2024 2023 Six Months Ended June 30, 2024 2023 Balance at beginning of period $ 156 $ 563 Net unrealized gain (loss) on foreign currency translation 383 (204 ) Balance at end of period $ 539 $ 359

Note 4 - Fair Value Measurement

Note 4 - Fair Value Measurement	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Fair Value Disclosures [Text Block]	4. Fair Value Measurement Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Three levels of inputs, of which the first two may • Level 1 • Level 2 1 not • Level 3 no 3 The Company’s fair value hierarchies for its financial assets and liabilities, which require fair value measurement on a recurring basis are as follows: Total Level 1 Level 2 Level 3 June 30, 2024 Liabilities Warrant liabilities $ 49 $ — $ — $ 49 December 31, 2023 Liabilities Warrant liabilities $ 366 $ — $ — $ 366 The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 six June 30, 2024 Warrant Liabilities Balance as of December 31, 2023 $ 366 Loss on modification of warrant 109 Gain on revaluation of warrants (426 ) Balance as of June 30, 2024 $ 49 Refer to Note 11. Capitalization and Equity Structure – Warrants .

Note 5 - Inventories

Note 5 - Inventories	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Inventory Disclosure [Text Block]	5. Inventories Inventories as of June 30, 2024 December 31, 2023 June 30, 2024 December 31, 2023 Raw materials $ 3,983 $ 4,298 Work in progress 217 290 Finished goods 774 462 Inventories $ 4,974 $ 5,050

Note 6 - Revenue

Note 6 - Revenue	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	6. Revenue The Company’s medical device segment (EksoHealth) revenue is primarily generated through the sale and subscription of the EksoNR, Ekso Indego Therapy, and Ekso Indego Personal devices, along with the sale of support and maintenance contracts. Revenue from medical device product sales is recognized at the point in time when control of the product transfers to the customer. Transfer of control generally occurs upon shipment from the Company’s facility for sales of the EksoNR, Ekso Indego Therapy, and Ekso Indego Personal devices. Support and maintenance contracts extend coverage beyond the Company’s standard warranty agreements ranging from 12 to 48 months. Revenue is recognized evenly over the term of the contracts. Revenue from medical device subscriptions is recognized evenly over the contract term, typically over 24 The Company’s industrial device segment (EksoWorks) revenue is primarily generated through the sale of the upper body exoskeleton EVO and associated accessories. Revenue from industrial device sales is recognized at the point in time when control of the product transfers to the customer. Transfer of control generally occurs upon shipment from the Company’s facility. Deferred Revenue Deferred revenue is comprised mainly of unearned revenue related to extended support and maintenance contracts, but also includes other offerings for which the Company has been paid in advance and earns revenue when the Company transfers control of the product or service. Deferred revenue consisted of the following: June 30, 2024 December 31, 2023 Deferred extended maintenance and support $ 3,786 3,993 Deferred device and advances 156 169 Total deferred revenues 3,942 4,162 Less current portion (1,926 ) (1,993 ) Deferred revenues, non-current $ 2,016 $ 2,169 On September 25, 2023, Deferred revenue activity consisted of the following for the six June 30, 2024 Beginning balance $ 4,162 Deferral of revenue 1,166 Recognition of deferred revenue (1,386 ) Ending balance $ 3,942 The Company expects to recognize approximatel y $1,162 of the deferred revenue during the remainder of 2024 2025 In addition to deferred revenue, the Company has a non-cancellable backlog of $2,872, 2024 2026, not and Disaggregation of Revenue The following table disaggregates the Company’s revenue by major source for the three June 30, 2024 EksoHealth EksoWorks Total Device revenue $ 3,656 $ 159 $ 3,815 Service and support 836 — 836 Subscriptions 146 — 146 Parts and other 146 7 153 $ 4,784 $ 166 $ 4,950 The following table disaggregates the Company’s revenue by major source for the three June 30, 2023 EksoHealth EksoWorks Total Device revenue $ 3,603 $ 7 $ 3,610 Service and support 722 — 722 Subscriptions 261 4 265 Parts and other 102 4 106 $ 4,688 $ 15 $ 4,703 The following table disaggregates the Company’s revenue by major source for the six June 30, 2024 EksoHealth EksoWorks Total Device revenue $ 6,241 $ 327 $ 6,568 Service and support 1,601 — 1,601 Subscriptions 290 — 290 Parts and other 211 36 247 $ 8,343 $ 363 $ 8,706 The following table disaggregates the Company’s revenue by major source for the six June 30, 2023 EksoHealth EksoWorks Total Device revenue $ 6,651 $ 118 $ 6,769 Service and support 1,366 — 1,366 Subscriptions 536 11 547 Parts and other 131 12 143 $ 8,684 $ 141 $ 8,825

Note 7 - Accrued Liabilities

Note 7 - Accrued Liabilities	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	7. Accrued Liabilities Accrued liabilities as of June 30, 2024 December 31, 2023 June 30, 2024 December 31, 2023 Salaries, benefits and related expenses $ 1,459 $ 2,058 Device warranty 417 461 Other 97 145 Total $ 1,973 $ 2,664 Warranty The current portion of the device warranty liability is classified as a component of Accrued liabilities, while the long-term portion of the device warranty liability is classified as a component of Other non-current liabilities in the condensed consolidated balance sheets. A reconciliation of the changes in the device warranty liability for the three six June 30, 2024 Three Months Ended Six Months Ended June 30, 2024 June 30, 2024 Balance at beginning of the period $ 526 $ 566 Additions for estimated future expense 195 316 Incurred costs (160 ) (321 ) Balance at end of the period $ 561 $ 561 Balance as of June 30, 2024 Current portion $ 417 Long-term portion 144 Total $ 561

Note 8 - Goodwill and Intangibl

Note 8 - Goodwill and Intangible Assets	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	8. Goodwill and Intangible Assets On December 5, 2022, Goodwill The Company accounted for the acquisition as a business combination in accordance with ASC 805, The Compan y determined no three six June 30, 2024 2023. Intangible Assets The following table summarizes the components of gross assets, accumulated amortization, and net carrying values for definite and indefinite lived intangible asset balances as of June 30, 2024 December 31, 2023: June 30, 2024 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Developed technology $ 2,310 $ (453 ) $ 1,857 Trade name 2,310 N/A 2,310 Intellectual property 460 — 460 Customer relationships 140 (28 ) 112 Total intangible assets $ 5,220 $ (481 ) $ 4,739 December 31, 2023 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Developed technology $ 2,310 $ (310 ) $ 2,000 Trade name 2,310 N/A 2,310 Intellectual property 460 — 460 Customer relationships 140 (18 ) 122 Total intangible assets $ 5,220 $ (328 ) $ 4,892 Definite lived intangible assets are amortized over their estimated lives using the straight line method, which is estimated as eight 12 eight one no ny determined no three six June 30, 2024 2023. The estimated future amortization expenses related to definite lived intangible assets as of June 30, 2024 Fiscal Year Amount 2024 - remainder $ 153 2025 345 2026 345 2027 345 2028 345 2029 and thereafter 896 Total $ 2,429 Amortization expense related to the acquired definite lived intangible assets wa s $77 and $ three June 30, 2024 2023, six June 30, 2024 2023,

Note 9 - Notes Payable, Net

Note 9 - Notes Payable, Net	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Long-Term Debt [Text Block]	9. Notes Payable, net PWB Term Loan In August 2020, first The Company was required to pay accrued interest on the current loan on the 13th August 13, 2023, August 17, 2023, August 13, 2026 470, The PWB Loan Agreement contains a liquidity covenant, which requires that the Company maintain cash in accounts of the lender or subject to control agreements in favor of the lender in an amount equal to at least the outstanding balance of the PWB Term Loan, which was $2,000 as of June 30, 2024 June 30, 2024 The interest rate of the PWB Term Loan is subject to increase in the event of late payment and after occurrence of and during the continuation of an event of default. The Company may The debt issuance costs and debt discounts combined with the stated interest resulted in an effective interest ra te of 8.74% and 8.87% fo three June 30, 2024 2023, six June 30, 2024 2023, taled $44 for each of the three June 30, 2024 2023, $87 six June 30, 2024 2023. The following table presents scheduled principal payments of the Company’s PWB Term Loan as of June 30, 2024 Period Amount 2024-2025 $ — 2026 2,000 Total principal payments 2,000 Less debt discount and issuance cost (5 ) Note payable, net $ 1,995 Current portion $ — Long-term portion 1,995 Note payable, net $ 1,995 Parker Hannifin Promissory Note In connection with the HMC Acquisition, on December 5, 2022, sixteen December 31, 2023 September 30, 2027. The Promissory Note, upon the occurrence of an event of default, allows for the levying of interest equal to the lesser of (a) 5% per annum and (b) the maximum interest rate permitted under applicable law on the then entire outstanding principal balance, and also for the acceleration of all outstanding liabilities and obligations, making them immediately payable. Under the terms of the Promissory Note, the following occurrences constitute a default, and could, upon written notice or declaration by Parker, allow for the levying of interest and or the acceleration of principal outstanding: (i) failure to pay any amount of the principal when due and payable, (ii) the dissolution of the Company (including the declaration of bankruptcy), and (iii) the acquisition of the Company by another entity or the sale of substantially all of its assets to another entity. The Company recorded the Promissory Note of $4,055 in its condensed consolidated balance sheets under the captions Notes Payable, Current and Notes Payable, Net, estimating an implicit discount rate of 7.5% via reference to the interest charged on the Company's PWB Term Loan and other relevant economic factors present at the execution date of the Promissory Note. The amortization of debt discounts resulted in an effective interest r ate of 7.05% and 7.50% f three June 30, 2024 2023, six June 30, 2024 2023, as $70 and three June 30, 2024 2023, six June 30, 2024 2023, The following table presents scheduled principal payments of the Company's Promissory Note as of June 30, 2024 Period Amount 2024 - remainder $ 625 2025 1,250 2026 1,250 2027 938 Total principal payments 4,063 Less debt discount (456 ) Note payable, net $ 3,607 Current portion 1,250 Long-term portion 2,357 Note payable, net $ 3,607

Note 10 - Lease Obligations

Note 10 - Lease Obligations	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	10. Lease Obligations The Company's operating lease agreement for its headquarters and manufacturing facility in San Rafael, California (the "San Rafael Lease") commenced in July 2022 October 2026, three The San Rafael Lease constitutes an operating lease under ASC 842 July 2022 October 2026. three The Company's operating lease agreement for its office in Hamburg, Germany (the "Hamburg Lease") commenced in May 2022 June 2025 one five The Hamburg Lease constitutes a lease under ASC 842, May 2022 June 2025. five m the lease liability calculation and expensed as incurred. The Company records a straight-line monthly rent expense for this lease equal to the sum of all fixed lease payments divided by the number of months in the lease term. The Company entered into an operating lease agreement for its shared service and manufacturing facility in Brecksville, Ohio (the "Ohio Lease"), commencing in June 2024 July 2027, three July 2024, 14. Commitments and Contingencies – Material Contracts The Company has determined that the Ohio Lease constitutes an operating lease under ASC 842 July 2024 July 2027. three would make exercise reasonably certain. Fixed lease payments for identified lease components over the identified term were discounted at the Company's estimated incremental borrowing rate as of the date of contract execution and are reflected in th The Company’s future lease payments as of June 30, 2024 Periods Operating Leases 2024 - remainder $ 248 2025 483 2026 432 2027 41 Total lease payments 1,204 Less: imputed interest (115 ) Present value of lease liabilities $ 1,089 Weighted-average remaining lease term (in years) 2.38 Weighted-average discount rate 8.3 % Lease expense under the Company’s operating leases w as $135 and $1 38 three June 30, 2024 2023 six June 30, 2024 2023

Note 11 - Capitalization and Eq

Note 11 - Capitalization and Equity Structure	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Equity [Text Block]	11. Capitalization and Equity Structure Summary The Company’s authorized capital stock at June 30, 2024 December 31, 2023 June 30, 2024 December 31, 2023 14,848 January 2024 On January 10, 2024, “January 2024 January 2024 January 2024 At the Market Offering In October 2020, may may June 2023, may not an $6.75 per share. During the three June 30, 2024, six June 30, 2024, not three six June 30, 2023. June 30, 2024, Warrants Warrants outstanding as of June 30, 2024 December 31, 2023 Source Exercise Price Remaining term (Years) December 31, 2023 Issued Expired Exercised June 30, 2024 2021 Warrants $ 12.81 1.6 273 — — — 273 June 2020 Investor Warrants $ 5.18 1.4 127 — — — 127 June 2020 Placement Agent Warrants $ 5.64 0.9 39 — — — 39 December 2019 Warrants $ 8.10 1.0 556 — — — 556 December 2019 Placement Agent Warrants $ 8.44 0.5 52 — — — 52 May 2019 Warrants $ 1.55 — 193 — (193 ) — — 1,240 — (193 ) — 1,047 No warrants were exercised during the three six June 30, 2024 2023 2021 In February 2021, "2021 2021 five February 11, 2026. In addition, the 2021 2021 2021 not may 2021 2021 2021 The 2021 2021 2021 30 2021 2021 five 2021 The warrant liability related to the 2021 3 2021 June 30, 2024 December 31, 2023 Current share price $ 1.06 $ 2.50 Conversion price $ 12.81 $ 12.81 Risk-free interest rate 4.86 % 4.20 % Expected term (years) 1.61 2.11 Volatility of stock 97.1 % 76.5 % June 2020 In June 2020, "June 2020 June 2020 five one December 10, 2025. In addition, the June 2020 June 2020 June 2020 not may June 2020 June 2020 The June 2020 The June 2020 June 2020 June 2020 June 2020 June 2020 June 2020 30 June 2020 June 2020 June 2020 The warrant liability related to the June 2020 3 June 2020 June 30, 2024 December 31, 2023 Current share price $ 1.06 $ 2.50 Conversion price $ 5.18 $ 5.18 Risk-free interest rate 4.92 % 4.26 % Expected term (years) 1.44 1.94 Volatility of stock 97.6 % 78.2 % June 2020 In June 2020, "June 2020 June 2020 June 2020 June 7, 2025. Because of the put-option provision in the June 2020 The warrant liability related to the June 2020 3 June 2020 June 30, 2024 December 31, 2023 Current share price $ 1.06 $ 2.50 Conversion price $ 5.64 $ 5.64 Risk-free interest rate 5.12 % 4.54 % Expected term (years) 0.94 1.44 Volatility of stock 112.6 % 83.0 % December 2019 In December 2019, "December 2019 "December 2019 December 2019 five June 21, 2025. The December 2019 December 2019 December 2019 December 2019 December 2019 30 December 2019 December 2019 five December 2019 The warrant liability related to the December 2019 3 December 2019 June 30, 2024 December 31, 2023 Current share price $ 1.06 $ 2.50 Conversion price $ 8.10 $ 8.10 Risk-free interest rate 5.11 % 4.53 % Expected term (years) 0.97 1.47 Volatility of stock 112.4 % 82.3 % December 2019 In December 2019, December 2019 "December 2019 December 2019 December 2019 December 18, 2025. The warrant liability related to the December 2019 3 December 2019 June 30, 2024 December 31, 2023 Current share price $ 1.06 $ 2.50 Conversion price $ 8.44 $ 8.44 Risk-free interest rate 5.35 % 4.82 % Expected term (years) 0.47 0.97 Volatility of stock 99.4 % 85.2 % Management has assessed that the likelihood of a Change of Control (as defined in the December 2019 December 2019 May 2019 In May 2019, "May 2019 "May 2019 The May 2019 five May 2024. The warrant liability related to the May 2019 3 May 2019 May 2019 June 30, 2024 December 31, 2023 Share price N/A $ 1.88 (1) Conversion price N/A $ 3.52 Risk-free interest rate N/A 5.3 % Expected term (years) — 0.4 Volatility of stock N/A 77.5 % ( 1 December 31, 2023, first 2024, 25%

Note 12 - Stock-based Compensat

Note 12 - Stock-based Compensation	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	12. Stock-based Compensation Shares available for grant The Company's Amended and Restated 2014 "2014 January 31, 2024. 2024 no 2014 June 6, 2024, 2014 2014 2014 April 15, 2034, 2014 June 30, 2024, 2014 were availabl Stock Options The following table summarizes information about the Company’s stock options outstanding as of June 30, 2024 six Weighted- Average Weighted- Remaining Aggregate Stock Average Contractual Intrinsic Awards Exercise Price Life (Years) Value Balance as of December 31, 2023 252 $ 36.17 Options cancelled (60 ) 49.74 Balance as of June 30, 2024 192 $ 31.95 3.91 $ — Vested and expected to vest as of June 30, 2024 192 $ 31.95 3.91 $ — Exercisable as of June 30, 2024 192 $ 31.96 3.91 $ — There were no stock options awarded during the three six June 30, 2024 2023 June 30, 2024 Restricted Stock Units The Company issues time-based restricted stock units (“RSUs”) and performance-based restricted stock units ("PSUs") to employees and non-employees. Each RSU and PSU represents the right to receive one Combined RSU and PSU activity for the six June 30, 2024 Weighted- Number of Average Grant Shares Date Fair Value Unvested as of December 31, 2023 1,305 $ 1.67 Granted 313 1.12 Vested (494 ) 1.80 Forfeited (42 ) 1.81 Unvested as of June 30, 2024 1,082 $ 1.44 As of June 30, 2024 $999 of total unrecognized compensation expense related to unvested RSUs and PSUs was expected to be recognized over a weighted average period of 1.14 ye Compensation Expense Stock-based compensation expense is included in the condensed consolidated statements of operations and comprehensive loss in general and administrative, research and development, or sales and marketing expenses, depending on the nature of the services provided. Stock-based compensation expense related to options, RSUs and PSUs was recorded as follows: Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Sales and marketing $ 6 $ 76 $ 58 $ 140 Research and development 81 131 171 213 General and administrative 198 307 431 585 $ 285 $ 514 $ 660 $ 938 401 During the six June 30, 2024 2023, d and 161 shares of common stock with a fair value of an 401 December 31, 2023 2022. The expense for the 401 six June 30, 2024 2023

Note 13 - Income Taxes

Note 13 - Income Taxes	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Income Tax Disclosure [Text Block]	13. Income Taxes There were no six June 30, 2024 not

Note 14 - Commitments and Conti

Note 14 - Commitments and Contingencies	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	14. Commitments and Contingencies Material Contracts The Company has two In connection with the HMC Acquisition, the Company assumed two The Vanderbilt Exoskeleton License Agreement was entered into as of October 15, 2012 April 29, 2038, The Vanderbilt Knee License Agreement was entered into as of March 1, 2022 February 15, 2041, July 31, 2028 Purchase Obligations The Company purchases components from a variety of suppliers and uses contract manufacturers to provide manufacturing services for its products. Purchase obligations are defined as agreements that are enforceable and legally binding and that specify all significant terms, including: fixed or minimum quantities to be purchased; fixed, minimum or variable price provisions; and the approximate timing of the transaction. The Company had purchase obligations primarily for purchases of inventory and manufacturing related service contracts totaling $2,137 as of June 30, 2024 one December 31, 2023 may The Company has operating lease commitments totaling $1,204 payable over 37 months related to the San Rafael Lease, the Ohio Lease, and the Hamburg Lease 10. Lease Obligations Loss Contingencies In the normal course of business, the Company is subject to various legal matters. In the opinion of management, the resolution of such matters will not

Note 15 - Net Loss Per Share

Note 15 - Net Loss Per Share	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Earnings Per Share [Text Block]	15. Net Loss Per Share The following table sets forth the computation of basic and diluted net loss per share: Three Months Ended Six Months Ended June 30, June 30, 2024 2023 2024 2023 Numerator: Net loss applicable to common stockholders, basic and diluted $ (2,416 ) $ (4,230 ) $ (5,845 ) $ (8,619 ) Denominator: Weighted-average number of shares, basic and diluted 18,224 13,637 17,822 13,467 Net loss per common share, basic and diluted $ (0.13 ) $ (0.31 ) $ (0.33 ) $ (0.64 ) The following table sets forth potential shares of common stock that are not Three Months Ended Six Months Ended June 30, June 30, 2024 2023 2024 2023 Options to purchase common stock 192 261 192 261 Restricted stock units 1,082 1,555 1,082 1,555 Warrants for common stock 1,047 1,240 1,047 1,240 Total common stock equivalents 2,321 3,056 2,321 3,056

Note 16 - Segment Disclosures

Note 16 - Segment Disclosures	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	16. Segment Disclosures The Company has two The Company evaluates performance and allocates resources based on segment gross profit margin. The Company does not not Segment reporting information is as follows: EksoHealth EksoWorks Total Three months ended June 30, 2024 Revenue $ 4,784 $ 166 $ 4,950 Cost of revenue 2,196 117 2,313 Gross profit $ 2,588 $ 49 $ 2,637 Three months ended June 30, 2023 Revenue $ 4,688 $ 15 $ 4,703 Cost of revenue 2,421 28 2,449 Gross profit $ 2,267 $ (13 ) $ 2,254 EksoHealth EksoWorks Total Six months ended June 30, 2024 Revenue $ 8,343 $ 363 $ 8,706 Cost of revenue 3,852 266 4,118 Gross profit $ 4,491 $ 97 $ 4,588 Six months ended June 30, 2023 Revenue $ 8,684 $ 141 $ 8,825 Cost of revenue 4,372 199 4,571 Gross profit $ 4,312 $ (58 ) $ 4,254 The Company operates in the following regions: ( 1 2 3 10% three six June 30, 2024 2023 Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Americas United States $ 2,589 $ 3,684 $ 4,886 $ 6,642 Canada 330 6 352 8 Mexico — — 9 3 Other — — — — Americas revenue 2,919 3,691 5,247 6,653 EMEA France 522 — 868 1 Germany 418 52 543 296 Romania 181 475 181 475 Poland 57 284 96 511 Other 338 51 659 335 EMEA revenue 1,516 862 2,347 1,618 APAC Hong Kong 108 118 122 297 Indonesia 301 — 636 — Other 106 32 354 257 APAC revenue 515 150 1,112 554 Total Revenue $ 4,950 $ 4,703 $ 8,706 $ 8,825

Note 17 - Related Party Transac

Note 17 - Related Party Transactions	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	17. Related Party Transactions On February 4, 2023, July 2017. one two The Company's total settlement amount was $325 and to be paid in cash over fourteen first twelve April 2024. f $0 June 30, 2024 December 31, 2023

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2024
Insider Trading Arr Line Items
Material Terms of Trading Arrangement [Text Block]		During the quarter ended June 30, 2024, no 16a 1 10b5 1 10b5 1 408.
Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation and Consolidation The accompanying condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10 December 31, 2023 March 4, 2024. In the opinion of management, the accompanying unaudited condensed consolidated financial statements have been prepared on a consistent basis with the audited consolidated financial statements for the fiscal year ended December 31, 2023 The results of operations for the three six June 30, 2024 not December 31, 2024 The condensed consolidated financial statements include the financial statements of Ekso Bionics Holdings, Inc. and its subsidiaries. All significant transactions and balances between Ekso Bionics Holdings, Inc. and its subsidiaries have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. For the Company, these estimates include, but are not
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency The assets and liabilities of foreign subsidiaries and equity investments, where the local currency is the functional currency, are translated from their respective functional currencies into U.S. dollars at the rates in effect at the balance sheet date, and revenue and expense amounts are translated at average rates during the period, with resulting foreign currency translation adjustments recorded in accumulated other comprehensive income as a component of stockholders’ equity. Gains and losses from the re-measurement of balances denominated in currencies other than the entities' functional currencies, are recorded in other expense, net in the accompanying condensed consolidated statements of operations and comprehensive loss.
Inventory, Policy [Policy Text Block]	Inventory Inventories are recorded at the lower of cost or net realizable value. Cost is computed using the standard cost method, which approximates actual cost on a first first
Lessee, Leases [Policy Text Block]	Leases The Company records its leases in accordance with the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 842, Leases not may Lease expense is recognized over the expected lease term on a straight-line basis. Operating leases are recognized on the balance sheet as right-of-use assets, lease liabilities current and lease liabilities non-current. Leases with an initial term of 12 not
Revenue [Policy Text Block]	Revenue Recognition The Company records its revenue in accordance with ASC 606, Revenue from Contracts with Customers five For multiple-element arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are determined based on observable prices at which the Company separately sells its products or services. If a standalone selling price is not The Company exercised judgement to determine that a product return reserve was not not
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk and Other Risks and Uncertainties Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and accounts receivable. The Company has significant cash balances at foreign financial institutions which throughout the year regularly exceed the applicable country cash deposit insurance limits of approximately $100 two $250 not Accounts receivable are derived from the sale of products shipped and services performed for customers primarily located in the U.S., Europe, Asia, and Australia. Invoices are aged based on contractual terms with the customer. The Company reviews accounts receivable for collectability and provides an allowance for potential credit losses. The allowance for potential credit losses on trade receivables reflects the Company’s best estimate of probable losses inherent in the accounts receivable balance based on known troubled accounts, historical experience, and other currently available evidence. Payment terms and conditions vary by contract type, although terms generally include a requirement of payment within 30 90 not June 30, 2024 December 31, 2023 Many of the sales contracts with customers outside of the U.S. are settled in a foreign currency other than the U.S. dollar. The Company does not not The Company had two 10% June 30, 2024 (15% and 10%), as no December 31, 2023 During the three June 30, 2024 two 10% ue (11% and 10%), as three three June 30, 2023 During the six June 30, 2024 two 10% nue (12% and 10%), a two six June 30, 2023
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In November 2023, No. 2023 07, 280 2023 07" 2023 07 2023 07 December 15, 2023, December 15, 2024. not 2023 07 Accounting Pronouncements Adopted in 2024 In August 2020, No. 2020 06, 2020 06" 2020 06 may first 2024 not

Note 3 - Accumulated Other Co_2

Note 3 - Accumulated Other Comprehensive Income (Loss) (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Six Months Ended June 30, 2024 2023 Balance at beginning of period $ 156 $ 563 Net unrealized gain (loss) on foreign currency translation 383 (204 ) Balance at end of period $ 539 $ 359

Note 4 - Fair Value Measureme_2

Note 4 - Fair Value Measurement (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Total Level 1 Level 2 Level 3 June 30, 2024 Liabilities Warrant liabilities $ 49 $ — $ — $ 49 December 31, 2023 Liabilities Warrant liabilities $ 366 $ — $ — $ 366
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Warrant Liabilities Balance as of December 31, 2023 $ 366 Loss on modification of warrant 109 Gain on revaluation of warrants (426 ) Balance as of June 30, 2024 $ 49

Note 5 - Inventories (Tables)

Note 5 - Inventories (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Inventory, Current [Table Text Block]	June 30, 2024 December 31, 2023 Raw materials $ 3,983 $ 4,298 Work in progress 217 290 Finished goods 774 462 Inventories $ 4,974 $ 5,050

Note 6 - Revenue (Tables)

Note 6 - Revenue (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]	June 30, 2024 December 31, 2023 Deferred extended maintenance and support $ 3,786 3,993 Deferred device and advances 156 169 Total deferred revenues 3,942 4,162 Less current portion (1,926 ) (1,993 ) Deferred revenues, non-current $ 2,016 $ 2,169 Beginning balance $ 4,162 Deferral of revenue 1,166 Recognition of deferred revenue (1,386 ) Ending balance $ 3,942
Disaggregation of Revenue [Table Text Block]	EksoHealth EksoWorks Total Device revenue $ 3,656 $ 159 $ 3,815 Service and support 836 — 836 Subscriptions 146 — 146 Parts and other 146 7 153 $ 4,784 $ 166 $ 4,950 EksoHealth EksoWorks Total Device revenue $ 3,603 $ 7 $ 3,610 Service and support 722 — 722 Subscriptions 261 4 265 Parts and other 102 4 106 $ 4,688 $ 15 $ 4,703 EksoHealth EksoWorks Total Device revenue $ 6,241 $ 327 $ 6,568 Service and support 1,601 — 1,601 Subscriptions 290 — 290 Parts and other 211 36 247 $ 8,343 $ 363 $ 8,706 EksoHealth EksoWorks Total Device revenue $ 6,651 $ 118 $ 6,769 Service and support 1,366 — 1,366 Subscriptions 536 11 547 Parts and other 131 12 143 $ 8,684 $ 141 $ 8,825

Note 7 - Accrued Liabilities (T

Note 7 - Accrued Liabilities (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	June 30, 2024 December 31, 2023 Salaries, benefits and related expenses $ 1,459 $ 2,058 Device warranty 417 461 Other 97 145 Total $ 1,973 $ 2,664
Product Maintenance And Warranty [Table Text Block]	Three Months Ended Six Months Ended June 30, 2024 June 30, 2024 Balance at beginning of the period $ 526 $ 566 Additions for estimated future expense 195 316 Incurred costs (160 ) (321 ) Balance at end of the period $ 561 $ 561 Balance as of June 30, 2024 Current portion $ 417 Long-term portion 144 Total $ 561

Note 8 - Goodwill and Intangi_2

Note 8 - Goodwill and Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	June 30, 2024 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Developed technology $ 2,310 $ (453 ) $ 1,857 Trade name 2,310 N/A 2,310 Intellectual property 460 — 460 Customer relationships 140 (28 ) 112 Total intangible assets $ 5,220 $ (481 ) $ 4,739 December 31, 2023 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Developed technology $ 2,310 $ (310 ) $ 2,000 Trade name 2,310 N/A 2,310 Intellectual property 460 — 460 Customer relationships 140 (18 ) 122 Total intangible assets $ 5,220 $ (328 ) $ 4,892
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Fiscal Year Amount 2024 - remainder $ 153 2025 345 2026 345 2027 345 2028 345 2029 and thereafter 896 Total $ 2,429

Note 9 - Notes Payable, Net (Ta

Note 9 - Notes Payable, Net (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Maturities of Long-Term Debt [Table Text Block]	Period Amount 2024-2025 $ — 2026 2,000 Total principal payments 2,000 Less debt discount and issuance cost (5 ) Note payable, net $ 1,995 Current portion $ — Long-term portion 1,995 Note payable, net $ 1,995 Period Amount 2024 - remainder $ 625 2025 1,250 2026 1,250 2027 938 Total principal payments 4,063 Less debt discount (456 ) Note payable, net $ 3,607 Current portion 1,250 Long-term portion 2,357 Note payable, net $ 3,607

Note 10 - Lease Obligations (Ta

Note 10 - Lease Obligations (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]	Periods Operating Leases 2024 - remainder $ 248 2025 483 2026 432 2027 41 Total lease payments 1,204 Less: imputed interest (115 ) Present value of lease liabilities $ 1,089 Weighted-average remaining lease term (in years) 2.38 Weighted-average discount rate 8.3 %

Note 11 - Capitalization and _2

Note 11 - Capitalization and Equity Structure (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Source Exercise Price Remaining term (Years) December 31, 2023 Issued Expired Exercised June 30, 2024 2021 Warrants $ 12.81 1.6 273 — — — 273 June 2020 Investor Warrants $ 5.18 1.4 127 — — — 127 June 2020 Placement Agent Warrants $ 5.64 0.9 39 — — — 39 December 2019 Warrants $ 8.10 1.0 556 — — — 556 December 2019 Placement Agent Warrants $ 8.44 0.5 52 — — — 52 May 2019 Warrants $ 1.55 — 193 — (193 ) — — 1,240 — (193 ) — 1,047
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	June 30, 2024 December 31, 2023 Current share price $ 1.06 $ 2.50 Conversion price $ 12.81 $ 12.81 Risk-free interest rate 4.86 % 4.20 % Expected term (years) 1.61 2.11 Volatility of stock 97.1 % 76.5 % June 30, 2024 December 31, 2023 Current share price $ 1.06 $ 2.50 Conversion price $ 5.18 $ 5.18 Risk-free interest rate 4.92 % 4.26 % Expected term (years) 1.44 1.94 Volatility of stock 97.6 % 78.2 % June 30, 2024 December 31, 2023 Current share price $ 1.06 $ 2.50 Conversion price $ 5.64 $ 5.64 Risk-free interest rate 5.12 % 4.54 % Expected term (years) 0.94 1.44 Volatility of stock 112.6 % 83.0 % June 30, 2024 December 31, 2023 Current share price $ 1.06 $ 2.50 Conversion price $ 8.10 $ 8.10 Risk-free interest rate 5.11 % 4.53 % Expected term (years) 0.97 1.47 Volatility of stock 112.4 % 82.3 % June 30, 2024 December 31, 2023 Current share price $ 1.06 $ 2.50 Conversion price $ 8.44 $ 8.44 Risk-free interest rate 5.35 % 4.82 % Expected term (years) 0.47 0.97 Volatility of stock 99.4 % 85.2 % June 30, 2024 December 31, 2023 Share price N/A $ 1.88 (1) Conversion price N/A $ 3.52 Risk-free interest rate N/A 5.3 % Expected term (years) — 0.4 Volatility of stock N/A 77.5 %

Note 12 - Stock-based Compens_2

Note 12 - Stock-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Weighted- Average Weighted- Remaining Aggregate Stock Average Contractual Intrinsic Awards Exercise Price Life (Years) Value Balance as of December 31, 2023 252 $ 36.17 Options cancelled (60 ) 49.74 Balance as of June 30, 2024 192 $ 31.95 3.91 $ — Vested and expected to vest as of June 30, 2024 192 $ 31.95 3.91 $ — Exercisable as of June 30, 2024 192 $ 31.96 3.91 $ —
Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]	Weighted- Number of Average Grant Shares Date Fair Value Unvested as of December 31, 2023 1,305 $ 1.67 Granted 313 1.12 Vested (494 ) 1.80 Forfeited (42 ) 1.81 Unvested as of June 30, 2024 1,082 $ 1.44
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Sales and marketing $ 6 $ 76 $ 58 $ 140 Research and development 81 131 171 213 General and administrative 198 307 431 585 $ 285 $ 514 $ 660 $ 938

Note 15 - Net Loss Per Share (T

Note 15 - Net Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended Six Months Ended June 30, June 30, 2024 2023 2024 2023 Numerator: Net loss applicable to common stockholders, basic and diluted $ (2,416 ) $ (4,230 ) $ (5,845 ) $ (8,619 ) Denominator: Weighted-average number of shares, basic and diluted 18,224 13,637 17,822 13,467 Net loss per common share, basic and diluted $ (0.13 ) $ (0.31 ) $ (0.33 ) $ (0.64 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended Six Months Ended June 30, June 30, 2024 2023 2024 2023 Options to purchase common stock 192 261 192 261 Restricted stock units 1,082 1,555 1,082 1,555 Warrants for common stock 1,047 1,240 1,047 1,240 Total common stock equivalents 2,321 3,056 2,321 3,056

Note 16 - Segment Disclosures (

Note 16 - Segment Disclosures (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	EksoHealth EksoWorks Total Three months ended June 30, 2024 Revenue $ 4,784 $ 166 $ 4,950 Cost of revenue 2,196 117 2,313 Gross profit $ 2,588 $ 49 $ 2,637 Three months ended June 30, 2023 Revenue $ 4,688 $ 15 $ 4,703 Cost of revenue 2,421 28 2,449 Gross profit $ 2,267 $ (13 ) $ 2,254 EksoHealth EksoWorks Total Six months ended June 30, 2024 Revenue $ 8,343 $ 363 $ 8,706 Cost of revenue 3,852 266 4,118 Gross profit $ 4,491 $ 97 $ 4,588 Six months ended June 30, 2023 Revenue $ 8,684 $ 141 $ 8,825 Cost of revenue 4,372 199 4,571 Gross profit $ 4,312 $ (58 ) $ 4,254
Revenue from External Customers by Geographic Areas [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Americas United States $ 2,589 $ 3,684 $ 4,886 $ 6,642 Canada 330 6 352 8 Mexico — — 9 3 Other — — — — Americas revenue 2,919 3,691 5,247 6,653 EMEA France 522 — 868 1 Germany 418 52 543 296 Romania 181 475 181 475 Poland 57 284 96 511 Other 338 51 659 335 EMEA revenue 1,516 862 2,347 1,618 APAC Hong Kong 108 118 122 297 Indonesia 301 — 636 — Other 106 32 354 257 APAC revenue 515 150 1,112 554 Total Revenue $ 4,950 $ 4,703 $ 8,706 $ 8,825

Note 1 - Organization (Details

Note 1 - Organization (Details Textual) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Retained Earnings (Accumulated Deficit)	$ (244,990)		$ (239,145)
Net Cash Provided by (Used in) Operating Activities	(6,136)	$ (7,117)
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents	5,885
Debt Covenant, Covenant Compliance, Unrestricted Cash	2,000
Unrestricted Cash	$ 3,885

Note 2 - Basis of Presentatio_2

Note 2 - Basis of Presentation and Summary of Significant Accounting Policies and Estimates (Details Textual) - Customer Concentration Risk [Member]	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Accounts Receivable [Member]
Number Of Customers			2
Accounts Receivable [Member] | Customer A [Member]
Concentration Risk, Percentage			15%
Accounts Receivable [Member] | Customer B [Member]
Concentration Risk, Percentage			10%
Revenue from Contract with Customer Benchmark [Member]
Number Of Customers	2	3	2	2
Revenue from Contract with Customer Benchmark [Member] | Customer A [Member]
Concentration Risk, Percentage	11%	18%	12%	16%
Revenue from Contract with Customer Benchmark [Member] | Customer B [Member]
Concentration Risk, Percentage	10%	14%	10%	13%
Revenue from Contract with Customer Benchmark [Member] | Customer C [Member]
Concentration Risk, Percentage		10%

Note 3 - Accumulated Other Co_3

Note 3 - Accumulated Other Comprehensive Income (Loss) - Disclosure of Changes in Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Balance	$ 12,606	$ 25,442
Net unrealized gain (loss) on foreign currency translation	383	(204)
Balance	12,059	17,807
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]
Balance	156	563
Balance	$ 539	$ 359

Note 4 - Fair Value Measureme_3

Note 4 - Fair Value Measurement - Fair Value Hierarchies (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Warrant liabilities	$ 49	$ 366
Fair Value, Inputs, Level 1 [Member]
Warrant liabilities	0	0
Fair Value, Inputs, Level 2 [Member]
Warrant liabilities	0	0
Fair Value, Inputs, Level 3 [Member]
Warrant liabilities	$ 49	$ 366

Note 4 - Fair Value Measureme_4

Note 4 - Fair Value Measurement - Changes in Fair Value (Details) - Derivative Financial Instruments, Liabilities [Member] $ in Thousands	6 Months Ended
	Jun. 30, 2024 USD ($)
Balance	$ 366
Loss on modification of warrant	109
Gain on revaluation of warrants	(426)
Balance	$ 49

Note 5 - Inventories - Inventor

Note 5 - Inventories - Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Raw materials	$ 3,983	$ 4,298
Work in progress	217	290
Finished goods	774	462
Inventories	$ 4,974	$ 5,050

Note 6 - Revenue 1 (Details Tex

Note 6 - Revenue 1 (Details Textual) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Sep. 25, 2023
Contract With Customer, Liability, Non-Cancellable Backlog	$ 2,872
Parker [Member]
Deferred Revenue, Warranty Claim Lump Sum		$ 700
Minimum [Member] | Ekso Health [Member]
Contracts With Customer, Accounts Receivable, Payment Terms, Duration (Month)	12 months
Maximum [Member] | Ekso Health [Member]
Contracts With Customer, Accounts Receivable, Payment Terms, Duration (Month)	48 months

Note 6 - Revenue 2 (Details Tex

Note 6 - Revenue 2 (Details Textual) $ in Thousands	Jun. 30, 2024 USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Amount	$ 1,162
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year)	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Revenue, Remaining Performance Obligation, Amount	$ 1,351
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year)	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01
Revenue, Remaining Performance Obligation, Amount	$ 1,429
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year)	1 year

Note 6 - Revenue - Deferred Rev

Note 6 - Revenue - Deferred Revenue (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Deferred extended maintenance and support	$ 3,786	$ 3,993
Deferred device and advances	156	169
Total deferred revenues	3,942	4,162
Less current portion	(1,926)	(1,993)
Deferred revenues, non-current	2,016	$ 2,169
Beginning balance	4,162
Deferral of revenue	1,166
Recognition of deferred revenue	(1,386)
Ending balance	$ 3,942

Note 6 - Revenue - Disaggregati

Note 6 - Revenue - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Revenue	$ 4,950	$ 4,703	$ 8,706	$ 8,825
Ekso Health [Member]
Revenue	4,784	4,688	8,343	8,684
Ekso Works [Member]
Revenue	166	15	363	141
Product [Member]
Revenue	3,815	3,610	6,568	6,769
Product [Member] | Ekso Health [Member]
Revenue	3,656	3,603	6,241	6,651
Product [Member] | Ekso Works [Member]
Revenue	159	7	327	118
Service [Member]
Revenue	836	722	1,601	1,366
Service [Member] | Ekso Health [Member]
Revenue	836	722	1,601	1,366
Service [Member] | Ekso Works [Member]
Revenue	0	0	0	0
Subscription [Member]
Revenue	146	265	290	547
Subscription [Member] | Ekso Health [Member]
Revenue	146	261	290	536
Subscription [Member] | Ekso Works [Member]
Revenue	0	4	0	11
Product and Service, Other [Member]
Revenue	153	106	247	143
Product and Service, Other [Member] | Ekso Health [Member]
Revenue	146	102	211	131
Product and Service, Other [Member] | Ekso Works [Member]
Revenue	$ 7	$ 4	$ 36	$ 12

Note 7 - Accrued Liabilities -

Note 7 - Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Salaries, benefits and related expenses	$ 1,459	$ 2,058
Device warranty	417	461
Other	97	145
Total	$ 1,973	$ 2,664

Note 7 - Accrued Liabilities _2

Note 7 - Accrued Liabilities - Warrant Liability (Details) - Warranty [Member] $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2024 USD ($)	Jun. 30, 2024 USD ($)
Balance at beginning of the period	$ 526	$ 566
Additions for estimated future expense	195	316
Incurred costs	(160)	(321)
Balance at end of the period	561	561
Current portion	417	417
Long-term portion	144	144
Total	$ 561	$ 561

Note 8 - Goodwill and Intangi_3

Note 8 - Goodwill and Intangible Assets (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Goodwill	$ 431		$ 431		$ 431
Below Market Lease, Amortization Period (Year)			1 year
Acquired Finite-Lived Intangible Asset, Amortization	$ 77	$ 82	$ 153	$ 163
Developed Technology Rights [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	8 years		8 years
Intellectual Property [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	12 years		12 years
Customer Relationships [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	8 years		8 years

Note 8 - Goodwill and Intangi_4

Note 8 - Goodwill and Intangible Assets - Goodwill and Intangible Assets Balances (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Intangibles, Net Carrying Amount	$ 2,429
Total intangible assets	5,220	$ 5,220
Total intangible assets	(481)	(328)
Total intangible assets	4,739	4,892
Trade Names [Member]
Intangibles, Gross Carrying Amount	2,310	2,310
Developed Technology Rights [Member]
Intangibles, Gross Carrying Amount	2,310	2,310
Intangibles, Accumulated Amortization	(453)	(310)
Intangibles, Net Carrying Amount	1,857	2,000
Intellectual Property [Member]
Intangibles, Gross Carrying Amount	460	460
Intangibles, Accumulated Amortization	0	0
Intangibles, Net Carrying Amount	460	460
Customer Relationships [Member]
Intangibles, Gross Carrying Amount	140	140
Intangibles, Accumulated Amortization	(28)	(18)
Intangibles, Net Carrying Amount	$ 112	$ 122

Note 8 - Goodwill and Intangi_5

Note 8 - Goodwill and Intangible Assets - Schedule of Finite Lived Intangible Assets (Details) $ in Thousands	Jun. 30, 2024 USD ($)
2024 - remainder	$ 153
2025	345
2026	345
2027	345
2028	345
2029 and thereafter	896
Total	$ 2,429

Note 9 - Notes Payable, Net (De

Note 9 - Notes Payable, Net (Details Textual) $ in Thousands		1 Months Ended	3 Months Ended			6 Months Ended
	Dec. 05, 2022 USD ($)	Aug. 30, 2020 USD ($)	Jun. 30, 2024 USD ($)	Mar. 31, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)
Term Loan [Member] | PWB Agreement [Member]
Line of Credit Facility, Maximum Borrowing Capacity		$ 2,000
Debt Instrument, Basis Spread on Variable Rate		0.50%
Debt Instrument, Interest Rate, Stated Percentage		4.50%
Long-Term Debt, Gross			$ 2,000	$ 2,000		$ 2,000
Debt Instrument, Covenant Compliance, Maximum Deposits Outside Of United States				$ 1,000
Line of Credit Facility, Interest Rate During Period			8.74%		8.87%	8.74%	8.70%
Interest Expense, Debt			$ 44		$ 44		$ 87
Subordinated Debt [Member] | Promissory Note [Member]
Debt Instrument, Basis Spread on Variable Rate	5%
Debt Instrument, Interest Rate, Stated Percentage	0%
Long-Term Debt, Gross			$ 4,063			$ 4,063
Line of Credit Facility, Interest Rate During Period			7.05%		7.50%	7.30%	7.50%
Interest Expense, Debt			$ 70		$ 79	$ 145	$ 159
Debt Instrument, Face Amount	$ 5,000
Debt Instrument, Periodic Payment, Number of Installments	16
Subordinated Debt			$ 4,055			$ 4,055
Debt Instrument, Discount Rate, Percentage						7.50%

Note 9 - Notes Payable, Net - S

Note 9 - Notes Payable, Net - Schedule of Principle Payments (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Mar. 31, 2024
Term Loan [Member] | PWB Agreement [Member]
2024-2025	$ 0
2026	2,000
Long-Term Debt, Gross	2,000	$ 2,000
Less debt discount and issuance cost	(5)
Note payable, net	1,995
Current portion	0
Long-term portion	1,995
2026	2,000
Total principal payments	2,000	$ 2,000
Note payable, net	1,995
Current portion	0
Long-term portion	1,995
Subordinated Debt [Member] | Promissory Note [Member]
2026	1,250
Long-Term Debt, Gross	4,063
Note payable, net	3,607
Current portion	1,250
Long-term portion	2,357
2024 - remainder	625
2025	1,250
2026	1,250
2027	938
Total principal payments	4,063
Less debt discount	456
Note payable, net	3,607
Current portion	1,250
Long-term portion	$ 2,357

Note 10 - Lease Obligations (De

Note 10 - Lease Obligations (Details Textual) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Mar. 31, 2024	Jul. 31, 2022	Feb. 28, 2022
Operating Lease, Expense	$ 135	$ 138	$ 271	$ 271
San Rafael California [Member]
Lessee, Operating Lease, Renewal Term (Year)					3 years	3 years
Brecksville Ohio [Member]
Lessee, Operating Lease, Renewal Term (Year)	3 years		3 years
Hamburg Germany [Member]
Lessee, Operating Lease, Renewal Term (Year)					5 years
Lessee Operating Lease, Number of Extension							1

Note 10 - Lease Obligations - S

Note 10 - Lease Obligations - Schedule of Future Lease Liabilities (Details) $ in Thousands	Jun. 30, 2024 USD ($)
2024 - remainder	$ 248
2025	483
2026	432
2027	41
Lessee, Operating Lease, Liability, to be Paid	1,204
Less: imputed interest	(115)
Present value of lease liabilities	$ 1,089
Weighted-average remaining lease term (in years) (Year)	2 years 4 months 17 days
Weighted-average discount rate	8.30%

Note 11 - Capitalization and _3

Note 11 - Capitalization and Equity Structure (Details Textual) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands		1 Months Ended			3 Months Ended			6 Months Ended
	Jan. 10, 2024	Feb. 28, 2021	Oct. 31, 2020	Jun. 30, 2020	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2019	Jun. 30, 2019	May 31, 2019
Common Stock, Shares Authorized (in shares)					141,429			141,429		141,429
Preferred Stock, Shares Authorized (in shares)					10,000			10,000		10,000
Common Stock, Shares, Outstanding (in shares)					18,444			18,444		14,848
Preferred Stock, Shares Outstanding (in shares)					0			0		0
Proceeds from Issuance of Common Stock								$ 4,017	$ 0
Stock Issued During Period, Value, New Issues			$ 5,000		$ 47	$ 3,970
Class Of Warrant Or Warrants Exercised (in shares)					0		0	0	0
Class Of Warrant Or Right Issued (in shares)								0
Class of Warrant or Right, Outstanding (in shares)					1,047			1,047		1,240
Common Stock, Shares, Issued (in shares)					18,444			18,444		14,848
Preferred Stock, Shares Issued (in shares)					0			0		0
A2021 Warrants [Member]
Class Of Warrant Or Right Issued (in shares)		273						0
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 12.81			$ 12.81			$ 12.81
Class of Warrant or Right Expiration Period (Year)		5 years
Class of Warrant or Right, Outstanding (in shares)					273			273		273
Warrants and Rights Outstanding, Term (Year)					1 year 7 months 6 days			1 year 7 months 6 days
June 2020 Investor Warrants [Member]
Class Of Warrant Or Right Issued (in shares)								0
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 5.18	$ 5.18			$ 5.18
Class of Warrant or Right, Outstanding (in shares)				874	127			127		127
Class of Warrant or Right Expiration Period (Year)				5 years 6 months
Warrants and Rights Outstanding, Term (Year)					1 year 4 months 24 days			1 year 4 months 24 days
June 2020 Placement Agent Warrants [Member]
Class Of Warrant Or Right Issued (in shares)				122				0
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 5.64	$ 5.64			$ 5.64
Class of Warrant or Right, Outstanding (in shares)					39			39		39
Warrants and Rights Outstanding, Term (Year)					10 months 24 days			10 months 24 days
December 2019 Warrants [Member]
Class Of Warrant Or Right Issued (in shares)								0
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)					$ 8.1			$ 8.1				$ 8.1
Class of Warrant or Right, Outstanding (in shares)					556			556		556		556
Warrants and Rights Outstanding, Term (Year)					1 year			1 year				5 years
December 2019 Placement Agent Warrants [Member]
Class Of Warrant Or Right Issued (in shares)								0
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)					$ 8.44			$ 8.44			$ 8.44
Class of Warrant or Right, Outstanding (in shares)					52			52		52	52
Warrants and Rights Outstanding, Term (Year)					6 months			6 months
May 2019 Warrants [Member]
Class Of Warrant Or Right Issued (in shares)								0
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)					$ 1.55			$ 1.55
Class of Warrant or Right, Outstanding (in shares)					0			0		193			444
Warrants and Rights Outstanding, Term (Year)													5 years
January 2024 Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)	2,968
Shares Issued, Price Per Share (in dollars per share)	$ 1.55
Proceeds from Issuance of Common Stock	$ 3,932
At the Market Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)					75		0	105	0
Proceeds from Issuance of Common Stock					$ 46			$ 85
Shares Issued, Average Price Per Share (in dollars per share)					$ 1.42			$ 1.43
Sale Of Stock, Stock Available For Issuance, Value								$ 4,134
At the Market Offering [Member] | Minimum [Member]
Share Price (in dollars per share)			$ 6.75

Note 11 - Capitalization and _4

Note 11 - Capitalization and Equity Structure - Schedule of Warrant Share Activity (Details) - $ / shares shares in Thousands	1 Months Ended		6 Months Ended
	Feb. 28, 2021	Jun. 30, 2020	Jun. 30, 2024	Dec. 31, 2019	Jun. 30, 2019	May 31, 2019
Balance (in shares)			1,240
Warrants issued (in shares)			0
Warrants expired (in shares)			(193)
Warrants exercised (in shares)			0
Balance (in shares)			1,047
A2021 Warrants [Member]
Exercise price (in dollars per share)	$ 12.81		$ 12.81
Term (Year)			1 year 7 months 6 days
Balance (in shares)			273
Warrants issued (in shares)	273		0
Warrants expired (in shares)			0
Warrants exercised (in shares)			0
Balance (in shares)			273
June 2020 Investor Warrants [Member]
Exercise price (in dollars per share)		$ 5.18	$ 5.18
Term (Year)			1 year 4 months 24 days
Balance (in shares)			127
Warrants issued (in shares)			0
Warrants expired (in shares)			0
Warrants exercised (in shares)			0
Balance (in shares)		874	127
June 2020 Placement Agent Warrants [Member]
Exercise price (in dollars per share)		$ 5.64	$ 5.64
Term (Year)			10 months 24 days
Balance (in shares)			39
Warrants issued (in shares)		122	0
Warrants expired (in shares)			0
Warrants exercised (in shares)			0
Balance (in shares)			39
December 2019 Warrants [Member]
Exercise price (in dollars per share)			$ 8.1		$ 8.1
Term (Year)			1 year		5 years
Balance (in shares)			556
Warrants issued (in shares)			0
Warrants expired (in shares)			0
Warrants exercised (in shares)			0
Balance (in shares)			556
December 2019 Placement Agent Warrants [Member]
Exercise price (in dollars per share)			$ 8.44	$ 8.44
Term (Year)			6 months
Balance (in shares)			52
Warrants issued (in shares)			0
Warrants expired (in shares)			0
Warrants exercised (in shares)			0
Balance (in shares)			52
May 2019 Warrants [Member]
Exercise price (in dollars per share)			$ 1.55
Term (Year)						5 years
Balance (in shares)			193
Warrants issued (in shares)			0
Warrants expired (in shares)			(193)
Warrants exercised (in shares)			0
Balance (in shares)			0

Note 11 - Capitalization and _5

Note 11 - Capitalization and Equity Structure - Schedule of Assumptions used in Black-Scholes Model to Measure Fair Value (Details)		Jun. 30, 2024	Dec. 31, 2023
A2021 Warrants [Member] | Measurement Input, Share Price [Member]
Warrant, measurement input		1.06	2.5
A2021 Warrants [Member] | Measurement Input, Conversion Price [Member]
Warrant, measurement input		12.81	12.81
A2021 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrant, measurement input		0.0486	0.042
A2021 Warrants [Member] | Measurement Input, Expected Term [Member]
Warrant, measurement input		1.61	2.11
A2021 Warrants [Member] | Measurement Input, Price Volatility [Member]
Warrant, measurement input		0.971	0.765
June 2020 Investor Warrants [Member] | Measurement Input, Share Price [Member]
Warrant, measurement input		1.06	2.5
June 2020 Investor Warrants [Member] | Measurement Input, Conversion Price [Member]
Warrant, measurement input		5.18	5.18
June 2020 Investor Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrant, measurement input		0.0492	0.0426
June 2020 Investor Warrants [Member] | Measurement Input, Expected Term [Member]
Warrant, measurement input		1.44	1.94
June 2020 Investor Warrants [Member] | Measurement Input, Price Volatility [Member]
Warrant, measurement input		0.976	0.782
June 2020 Placement Agent Warrants [Member] | Measurement Input, Share Price [Member]
Warrant, measurement input		1.06	2.5
June 2020 Placement Agent Warrants [Member] | Measurement Input, Conversion Price [Member]
Warrant, measurement input		5.64	5.64
June 2020 Placement Agent Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrant, measurement input		0.0512	0.0454
June 2020 Placement Agent Warrants [Member] | Measurement Input, Expected Term [Member]
Warrant, measurement input		0.94	1.44
June 2020 Placement Agent Warrants [Member] | Measurement Input, Price Volatility [Member]
Warrant, measurement input		1.126	0.83
December 2019 Warrants [Member] | Measurement Input, Share Price [Member]
Warrant, measurement input		1.06	2.5
December 2019 Warrants [Member] | Measurement Input, Conversion Price [Member]
Warrant, measurement input		8.1	8.1
December 2019 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrant, measurement input		0.0511	0.0453
December 2019 Warrants [Member] | Measurement Input, Expected Term [Member]
Warrant, measurement input		0.97	1.47
December 2019 Warrants [Member] | Measurement Input, Price Volatility [Member]
Warrant, measurement input		1.124	0.823
December 2019 Placement Agent Warrants [Member] | Measurement Input, Share Price [Member]
Warrant, measurement input		1.06	2.5
December 2019 Placement Agent Warrants [Member] | Measurement Input, Conversion Price [Member]
Warrant, measurement input		8.44	8.44
December 2019 Placement Agent Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrant, measurement input		0.0535	0.0482
December 2019 Placement Agent Warrants [Member] | Measurement Input, Expected Term [Member]
Warrant, measurement input		0.47	0.97
December 2019 Placement Agent Warrants [Member] | Measurement Input, Price Volatility [Member]
Warrant, measurement input		0.994	0.852
May 2019 Warrants [Member] | Measurement Input, Share Price [Member]
Warrant, measurement input	[1]		1.88
May 2019 Warrants [Member] | Measurement Input, Conversion Price [Member]
Warrant, measurement input			3.52
May 2019 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrant, measurement input			0.053
May 2019 Warrants [Member] | Measurement Input, Expected Term [Member]
Warrant, measurement input			0.4
May 2019 Warrants [Member] | Measurement Input, Price Volatility [Member]
Warrant, measurement input			0.775
[1]As of December 31, 2023, management determined that a financing event was likely in the first quarter of 2024, and reduced the share price used in the model by 25% in order to reflect the total amount that would be realized accordingly.

Note 12 - Stock-based Compens_3

Note 12 - Stock-based Compensation (Details Textual) - USD ($) shares in Thousands, $ in Thousands		3 Months Ended			6 Months Ended
	Jun. 06, 2024	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)		0		0	0	0
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount		$ 0			$ 0
Stock Issued During Period, Value, Employee Benefit Plan			$ 237	$ 249
Defined Contribution Plan, Employer Matching Contribution, Percent of Match					50%
Common Stock Contribution					$ 113	$ 219
Additional Paid-in Capital [Member]
Stock Issued During Period, Shares, Employee Benefit Plan (in shares)					163	161
Stock Issued During Period, Value, Employee Benefit Plan			$ 237	$ 249	$ 238	$ 249
Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)					313
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount		$ 999			$ 999
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)					1 year 1 month 20 days
Equity Incentive Plan 2014 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)	1,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)		4,724			4,724
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)		1,066			1,066

Note 12 - Stock-based Compens_4

Note 12 - Stock-based Compensation - Stock Option Outstanding (Details) - Equity Incentive Plan 2014 [Member] $ / shares in Units, shares in Thousands, $ in Thousands	6 Months Ended
	Jun. 30, 2024 USD ($) $ / shares shares
Balance (in shares) | shares	252
Balance (in dollars per share) | $ / shares	$ 36.17
Options cancelled (in shares) | shares	(60)
Options cancelled (in dollars per share) | $ / shares	$ 49.74
Balance (in shares) | shares	192
Balance (in dollars per share) | $ / shares	$ 31.95
Balance as of June 30, 2024 (Year)	3 years 10 months 28 days
Balance as of June 30, 2024 | $	$ 0
Vested and expected to vest as of June 30, 2024 (in shares) | shares	192
Vested and expected to vest as of June 30, 2024 (in dollars per share) | $ / shares	$ 31.95
Vested and expected to vest as of June 30, 2024 (Year)	3 years 10 months 28 days
Vested and expected to vest as of June 30, 2024 | $	$ 0
Exercisable as of June 30, 2024 (in shares) | shares	192
Exercisable as of June 30, 2024 (in dollars per share) | $ / shares	$ 31.96
Exercisable as of June 30, 2024 (Year)	3 years 10 months 28 days
Exercisable as of June 30, 2024 | $	$ 0

Note 12 - Stock-based Compens_5

Note 12 - Stock-based Compensation - RSU and PSU Activity (Details) - $ / shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Granted (in shares)	0	0	0	0
Restricted Stock Units (RSUs) [Member]
Balance (in shares)			1,305
Balance (in dollars per share)			$ 1.67
Granted (in shares)			313
Granted (in dollars per share)			$ 1.12
Vested (in shares)			(494)
Vested (in dollars per share)			$ 1.8
Forfeited (in shares)			(42)
Forfeited (in dollars per share)			$ 1.81
Balance (in shares)	1,082		1,082
Balance (in dollars per share)	$ 1.44		$ 1.44

Note 12 - Stock-based Compens_6

Note 12 - Stock-based Compensation - Stock Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Stock based compensation	$ 285	$ 514	$ 660	$ 938
Selling and Marketing Expense [Member]
Stock based compensation	6	76	58	140
Research and Development Expense [Member]
Stock based compensation	81	131	171	213
General and Administrative Expense [Member]
Stock based compensation	$ 198	$ 307	$ 431	$ 585

Note 14 - Commitments and Con_2

Note 14 - Commitments and Contingencies (Details Textual) $ in Thousands			6 Months Ended	18 Months Ended
	Mar. 01, 2022 USD ($)	Oct. 15, 2012 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2024 USD ($)	Dec. 31, 2023 USD ($)
Number Of License Agreements			2	2
Purchase Obligation			$ 2,137	$ 2,137	$ 2,783
Long-Term Purchase Commitment, Period (Year)			1 year
Lessee, Operating Lease, Liability, to be Paid			$ 1,204	$ 1,204
San Rafael, Brecksville, and Hamburg [Member]
Lessee, Operating Lease, Term of Contract (Year)			37 years	37 years
Royalty Agreement Terms [Member]
Royalty Percentage		3.75%
Royalty Expense	$ 75	$ 250		$ 100
Royalty Agreement Terms [Member] | Licensed Patent Products [Member]
Royalty Percentage		6%
Royalty Agreement Terms [Member] | Licensed Software Products [Member]
Royalty Percentage		3%
Sales Revenue Goods Net Excluding Government Sales [Member] | Royalty Agreement Terms [Member]
Royalty Percentage			1%
License Revenue [Member] | Royalty Agreement Terms [Member]
Royalty Percentage			21%

Note 15 - Net Loss Per Share -

Note 15 - Net Loss Per Share - Computation of Basic and Diluted Net Loss per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Net loss applicable to common stockholders, basic and diluted	$ (2,416)	$ (4,230)	$ (5,845)	$ (8,619)
Weighted-average number of shares, basic and diluted (in shares)	18,224	13,637	17,822	13,467
Net loss per common share, basic and diluted (in dollars per share)	$ (0.13)	$ (0.31)	$ (0.33)	$ (0.64)

Note 15 - Net Loss Per Share _2

Note 15 - Net Loss Per Share - Schedule of Antidilutive Securities (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Antidilutive Securities (in shares)	2,321	3,056	2,321	3,056
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities (in shares)	192	261	192	261
Restricted Stock [Member]
Antidilutive Securities (in shares)	1,082	1,555	1,082	1,555
Warrant [Member]
Antidilutive Securities (in shares)	1,047	1,240	1,047	1,240

Note 16 - Segment Disclosures_2

Note 16 - Segment Disclosures (Details Textual)	6 Months Ended
	Jun. 30, 2024
Number of Reportable Segments	2

Note 16 - Segment Disclosures -

Note 16 - Segment Disclosures - Segment Reporting Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Revenue	$ 4,950	$ 4,703	$ 8,706	$ 8,825
Cost of revenue	2,313	2,449	4,118	4,571
Gross profit	2,637	2,254	4,588	4,254
Ekso Health [Member]
Revenue	4,784	4,688	8,343	8,684
Cost of revenue	2,196	2,421	3,852	4,372
Gross profit	2,588	2,267	4,491	4,312
Ekso Works [Member]
Revenue	166	15	363	141
Cost of revenue	117	28	266	199
Gross profit	$ 49	$ (13)	$ 97	$ (58)

Note 16 - Segment Disclosures_3

Note 16 - Segment Disclosures - Geographic Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Revenue	$ 4,950	$ 4,703	$ 8,706	$ 8,825
UNITED STATES
Revenue	2,589	3,684	4,886	6,642
CANADA
Revenue	330	6	352	8
MEXICO
Revenue	0	0	9	3
Americas Other [Member]
Revenue	0	0	0	0
Americas [Member]
Revenue	2,919	3,691	5,247	6,653
FRANCE
Revenue	522	0	868	1
GERMANY
Revenue	418	52	543	296
ROMANIA
Revenue	181	475	181	475
POLAND
Revenue	57	284	96	511
EMEA Other [Member]
Revenue	338	51	659	335
EMEA [Member]
Revenue	1,516	862	2,347	1,618
HONG KONG
Revenue	108	118	122	297
INDONESIA
Revenue	301	0	636	0
APAC Other [Member]
Revenue	106	32	354	257
Asia Pacific [Member]
Revenue	$ 515	$ 150	$ 1,112	$ 554

Note 17 - Related Party Trans_2

Note 17 - Related Party Transactions (Details Textual) - Angel Pond Capital LLC [Member] - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Related Party Transaction, Amounts of Transaction	$ 325
Related Party Transaction, Payment Term (Year)	14 years
Accounts Payable	$ 0	$ 60
Initial Payment1 [Member]
Related Party Transaction, Amounts of Transaction	$ 145
Related Party Transaction, Payment Term (Year)	40 months
Initial Payment [Member]
Related Party Transaction, Amounts of Transaction	$ 15
Initial Payment2 [Member]
Related Party Transaction, Payment Term (Year)	12 years